Retinoblastoma: What the Neuroradiologist Needs to Know

References

1. 1.↵
   1. Dimaras H,
   2. Kimani K,
   3. Dimba EA, et al

   . Retinoblastoma. Lancet 2012;379:1436–46 doi:10.1016/S0140-6736(11)61137-9 pmid:22414599

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Dimaras H,
   2. Corson TW,
   3. Cobrinik D, et al

   . Retinoblastoma. Nat Rev Dis Primers 2015;1:15021 doi:10.1038/nrdp.2015.21 pmid:27189421

   CrossRefPubMed
3. 3.↵
   1. Shields JA,
   2. Leonard BC,
   3. Michelson JB, et al

   . B-scan ultrasonography in the diagnosis of atypical retinoblastomas. Can J Ophthalmol 1976;11:42–51 pmid:1247938

   PubMed
4. 4.↵
   1. Chawla B,
   2. Bhaskaran K,
   3. Dada T, et al

   . Evaluation of the role of ultrasound biomicroscopy in advanced retinoblastoma: a prospective study on Asian Indian children. Ophthalmic Genet 2020;1–6 doi:10.1080/13816810.2020.1737946 pmid:32176559

   CrossRefPubMed
5. 5.↵
   1. Kim JW,
   2. Ngai LK,
   3. Sadda S, et al

   . Retcam fluorescein angiography findings in eyes with advanced retinoblastoma. Br J Ophthalmol 2014;98:1666–71 doi:10.1136/bjophthalmol-2014-305180 pmid:25053763

   Abstract/FREE Full Text
6. 6.↵
   1. Lim LS,
   2. Dalvin LA,
   3. Ancona-Lezama D, et al

   . Retinoblastoma vascular perfusion and intra-arterial chemotherapy cycle requirements. Clin Exp Ophthalmol 2019;47:1164–72 doi:10.1111/ceo.13616 pmid:31432625

   CrossRefPubMed
7. 7.↵
   1. Bianciotto C,
   2. Shields CL,
   3. Iturralde JC, et al

   . Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology 2012;119:843–49 doi:10.1016/j.ophtha.2011.09.040 pmid:22137042

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Seider MI,
   2. Grewal DS,
   3. Mruthyunjaya P

   . Portable optical coherence tomography detection or confirmation of ophthalmoscopically invisible or indeterminate active retinoblastoma. Ophthalmic Surg Lasers Imaging Retina 2016;47:965–68 doi:10.3928/23258160-20161004-12 pmid:27759865

   CrossRefPubMed
9. 9.↵
   1. Gonzalez-Montpetit ME,
   2. Samara WA,
   3. Magrath GN, et al

   . Detection of minimally visible recurrent retinoblastoma by hand-held spectral-domain optical coherence tomography. J Pediatr Ophthalmol Strabismus 2017;54:e6–e8 doi:10.3928/01913913-20170201-03 pmid:28196267

   CrossRefPubMed
10. 10.↵
    1. Nadiarnykh O,
    2. Davidoiu V,
    3. Grafe MGO, et al

    . Phase-based OCT angiography in diagnostic imaging of pediatric retinoblastoma patients: abnormal blood vessels in post-treatment regression patterns. Biomed Opt Express 2019;10:2213–26 doi:10.1364/BOE.10.002213 pmid:31143490

    CrossRefPubMed
11. 11.↵
    1. de Graaf P,
    2. Göricke S,
    3. Rodjan F, et al

    . Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol 2012;42:2–14 doi:10.1007/s00247-011-2201-5 pmid:21850471

    CrossRefPubMed
12. 12.↵
    1. Rodjan F,
    2. de Graaf P,
    3. Moll AC, et al

    . Brain abnormalities on MR imaging in patients with retinoblastoma. AJNR Am J Neuroradiol 2010;31:1385–89 doi:10.3174/ajnr.A2102 pmid:20413604

    Abstract/FREE Full Text
13. 13.↵
    1. Galluzzi P,
    2. Hadjistilianou T,
    3. Cerase A, et al

    . Is CT still useful in the study protocol of retinoblastoma? AJNR Am J Neuroradiol 2009;30:1760–65 doi:10.3174/ajnr.A1716 pmid:19617447

    Abstract/FREE Full Text
14. 14.↵
    1. Marees T,
    2. Moll AC,
    3. Imhof SM, et al

    . Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008;100:1771–79 doi:10.1093/jnci/djn394 pmid:19066271

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Murray T

    . Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. Surv Ophthalmol 1998;43:288–89 doi:10.1016/s0039-6257(98)00043-5 pmid:9862317

    CrossRefPubMed
16. 16.↵
    1. Wong FL,
    2. Boice JD Jr.,
    3. Abramson DH, et al

    . Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997;278:1262–67 doi:10.1001/jama.1997.03550150066037 pmid:9333268

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Brisse HJ,
    2. Lumbroso L,
    3. Freneaux PC, et al

    . Sonographic, CT, and MR imaging findings in diffuse infiltrative retinoblastoma: report of two cases with histologic comparison. AJNR Am J Neuroradiol 2001;22:499–504 pmid:11237973

    Abstract/FREE Full Text
18. 18.↵
    1. Shields CL,
    2. Ghassemi F,
    3. Tuncer S, et al

    . Clinical spectrum of diffuse infiltrating retinoblastoma in 34 consecutive eyes. Ophthalmology 2008;115:2253–58 doi:10.1016/j.ophtha.2008.07.003 pmid:18962920

    CrossRefPubMedWeb of Science
19. 19.↵
    1. de Graaf P,
    2. van der Valk P,
    3. Moll AC, et al

    . Contrast-enhancement of the anterior eye segment in patients with retinoblastoma: correlation between clinical, MR imaging, and histopathologic findings. AJNR Am J Neuroradiol 2010;31:237–45 doi:10.3174/ajnr.A1825 pmid:19833805

    Abstract/FREE Full Text
20. 20.↵
    1. Galluzzi P,
    2. Cerase A,
    3. Hadjistilianou T, et al

    . Retinoblastoma: abnormal gadolinium enhancement of anterior segment of eyes at MR imaging with clinical and histopathologic correlation. Radiology 2003;228:683–90 doi:10.1148/radiol.2283020466 pmid:12881579

    CrossRefPubMed
21. 21.↵
    1. Chintagumpala M,
    2. Chevez-Barrios P,
    3. Paysse EA, et al

    . Retinoblastoma: review of current management. Oncologist 2007;12:1237–46 doi:10.1634/theoncologist.12-10-1237 pmid:17962617

    Abstract/FREE Full Text
22. 22.↵
    1. Kopelman JE,
    2. McLean IW,
    3. Rosenberg SH

    . Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology 1987;94:371–77 doi:10.1016/S0161-6420(87)33436-0 pmid:3587919

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Barkhof F,
    2. Smeets M,
    3. van der Valk P, et al

    . MR imaging in retinoblastoma. Eur Radiology 1997;7:726–31 doi:10.1007/BF02742934 pmid:9166573

    CrossRefPubMed
24. 24.↵
    1. Schueler AO,
    2. Hosten N,
    3. Bechrakis NE, et al

    . High resolution magnetic resonance imaging of retinoblastoma. Br J Ophthalmol 2003;87:330–35 doi:10.1136/bjo.87.3.330 pmid:12598449

    Abstract/FREE Full Text
25. 25.↵
    1. de Graaf P,
    2. Barkhof F,
    3. Moll AC, et al

    . Retinoblastoma: MR imaging parameters in detection of tumor extent. Radiology 2005;235:197–207 doi:10.1148/radiol.2351031301 pmid:15695620

    CrossRefPubMed
26. 26.↵
    1. Rauschecker AM,
    2. Patel CV,
    3. Yeom KW, et al

    . High-resolution MR imaging of the orbit in patients with retinoblastoma. Radiographics 2012;32:1307–26 doi:10.1148/rg.325115176 pmid:22977020

    CrossRefPubMed
27. 27.↵
    1. Sirin S,
    2. Schlamann M,
    3. Metz KA, et al

    . High-resolution MRI using orbit surface coils for the evaluation of metastatic risk factors in 143 children with retinoblastoma: part 1: MRI vs. histopathology. Neuroradiology 2015;57:805–14 doi:10.1007/s00234-015-1544-2 pmid:26041632

    CrossRefPubMed
28. 28.↵
    1. Khelfaoui F,
    2. Validire P,
    3. Auperin A, et al

    . Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer 1996;77:1206–13 doi:10.1002/(SICI)1097-0142(19960315)77:6<1206::AID-CNCR30>3.0.CO;2-3 pmid:8635145

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Chawla B,
    2. Sharma S,
    3. Sen S, et al

    . Correlation between clinical features, magnetic resonance imaging, and histopathologic findings in retinoblastoma: a prospective study. Ophthalmology 2012;119:850–56 doi:10.1016/j.ophtha.2011.09.037 pmid:22218144

    CrossRefPubMed
30. 30.↵
    1. Novetsky DE,
    2. Abramson DH,
    3. Kim JW, et al

    . Published International Classification of Retinoblastoma (ICRB) definitions contain inconsistencies—an analysis of impact. Ophthalmic Genet 2009;30:40–44 doi:10.1080/13816810802452168 pmid:19172510

    CrossRefPubMed
31. 31.↵
    1. Chévez-Barrios P,
    2. Eagle RC Jr.,
    3. Krailo M, et al

    . Study of unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy: a Children's Oncology Group study. J Clin Oncol 2019;37:2883–91 doi:10.1200/JCO.18.01808 pmid:31539297

    CrossRefPubMed
32. 32.↵
    1. Kashyap S,
    2. Meel R,
    3. Pushker N, et al

    . Phthisis bulbi in retinoblastoma. Clin Exp Ophthalmol 2011;39:105–10 doi:10.1111/j.1442-9071.2010.02426.x pmid:21040312

    CrossRefPubMed
33. 33.↵
    1. Shields JA,
    2. Shields CL,
    3. Suvarnamani C, et al

    . Retinoblastoma manifesting as orbital cellulitis. Am J Ophthalmol 1991;112:442–49 doi:10.1016/s0002-9394(14)76255-5 pmid:1928248

    CrossRefPubMed
34. 34.↵
    1. Shields CL,
    2. Shields JA,
    3. Baez K, et al

    . Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer 1994;73:692–98 doi:10.1002/1097-0142(19940201)73:3<692::AID-CNCR2820730331>3.0.CO;2-8 pmid:8299091

    CrossRefPubMed
35. 35.↵
    1. Cuenca A,
    2. Giron F,
    3. Castro D, et al

    . Microscopic scleral invasion in retinoblastoma: clinicopathological features and outcome. Arch Ophthalmol 2009;127:1006–10 doi:10.1001/archophthalmol.2009.174 pmid:19667337

    CrossRefPubMed
36. 36.↵
    1. Brisse HJ,
    2. Guesmi M,
    3. Aerts I, et al

    . Relevance of CT and MRI in retinoblastoma for the diagnosis of postlaminar invasion with normal-size optic nerve: a retrospective study of 150 patients with histological comparison. Pediatr Radiol 2007;37:649–56 doi:10.1007/s00247-007-0491-4 pmid:17479257

    CrossRefPubMed
37. 37.↵
    1. Li Z,
    2. Guo J,
    3. Xu X, et al

    . Diagnosis of postlaminar optic nerve invasion in retinoblastoma with MRI features. J Magn Reson Imaging 2020;51:1045–52 doi:10.1002/jmri.26961 pmid:31617290

    CrossRefPubMed
38. 38.↵
    1. Magramm I,
    2. Abramson DH,
    3. Ellsworth RM

    . Optic nerve involvement in retinoblastoma. Ophthalmology 1989;96:217–22 doi:10.1016/S0161-6420(89)32910-1 pmid:2704542

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Brisse HJ,
    2. de Graaf P,
    3. Galluzzi P

    , et al. Assessment of early-stage optic nerve invasion in retinoblastoma using high-resolution 1.5 Tesla MRI with surface coils: a multicentre, prospective accuracy study with histopathological correlation. Eur Radio 2015;25:1443–52 doi:10.1007/s00330-014-3514-1 pmid:25433413

    CrossRefPubMed
40. 40.↵
    1. Cui Y,
    2. Luo R,
    3. Wang R, et al

    . Correlation between conventional MR imaging combined with diffusion-weighted imaging and histopathologic findings in eyes primarily enucleated for advanced retinoblastoma: a retrospective study. Eur Radiol 2018;28:620–29 doi:10.1007/s00330-017-4993-7 pmid:28786011

    CrossRefPubMed
41. 41.↵
    1. Lee BJ,
    2. Kim JH,
    3. Kim DH, et al

    . The validity of routine brain MRI in detecting post-laminar optic nerve involvement in retinoblastoma. Br J Ophthalmol 2012;96:1237–41 doi:10.1136/bjophthalmol-2012-301502

    Abstract/FREE Full Text
42. 42.↵
    1. Khurana A,
    2. Eisenhut CA,
    3. Wan W, et al

    . Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma. Eur Radiol 2013;23:1271–80 doi:10.1007/s00330-012-2707-8 pmid:23160663

    CrossRefPubMed
43. 43.↵
    1. de Graaf P,
    2. Moll AC,
    3. Imhof SM, et al

    . Retinoblastoma and optic nerve enhancement on MRI: not always extraocular tumour extension. Br J Ophthalmol 2006;90:800–01 doi:10.1136/bjo.2005.089383 pmid:16714275

    FREE Full Text
44. 44.↵
    1. Lemke AJ,
    2. Kazi I,
    3. Mergner U, et al

    . Retinoblastoma—MR appearance using a surface coil in comparison with histopathological results. Eur Radiol 2007;17:49–60 doi:10.1007/s00330-006-0197-2 pmid:16636801

    CrossRefPubMed
45. 45.↵
    1. Song KD,
    2. Eo H,
    3. Kim JH, et al

    . Can preoperative MR imaging predict optic nerve invasion of retinoblastoma? Eur J Radiol 2012;81:4041–45 doi:10.1016/j.ejrad.2012.03.034 pmid:23017191

    CrossRefPubMed
46. 46.↵
    1. Wilson MW,
    2. Rodriguez-Galindo C,
    3. Billups C, et al

    . Lack of correlation between the histologic and magnetic resonance imaging results of optic nerve involvement in eyes primarily enucleated for retinoblastoma. Ophthalmology 2009;116:1558–63 doi:10.1016/j.ophtha.2009.02.018 pmid:19545904

    CrossRefPubMed
47. 47.↵
    1. Hiasat JG,
    2. Saleh A,
    3. Al-Hussaini M, et al

    . The predictive value of magnetic resonance imaging of retinoblastoma for the likelihood of high-risk pathologic features. Eur J Ophthalmol 2019;29:262–68 doi:10.1177/1120672118781200 pmid:29890860

    CrossRefPubMed
48. 48.↵
    1. de Jong MC,
    2. de Graaf P,
    3. Noij DP, et al

    . Diagnostic performance of magnetic resonance imaging and computed tomography for advanced retinoblastoma: a systematic review and meta-analysis. Ophthalmology 2014;121:1109–18 doi:10.1016/j.ophtha.2013.11.021 pmid:24589388

    CrossRefPubMedWeb of Science
49. 49.↵
    1. Shields CL,
    2. Mashayekhi A,
    3. Au AK, et al

    . The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006;113:2276–80 doi:10.1016/j.ophtha.2006.06.018 pmid:16996605

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Shields CL,
    2. Lally SE,
    3. Leahey AM, et al

    . Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol 2014;25:374–85 doi:10.1097/ICU.0000000000000091 pmid:25014750

    CrossRefPubMed
51. 51.↵
    1. Shields CL,
    2. Bas Z,
    3. Tadepalli S, et al

    . Long-term (20-year) real-world outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma in 964 eyes of 554 patients at a single centre. Br J Ophthalmol 2020;104:1548–55 doi:10.1136/bjophthalmol-2019-315572 pmid:32051141

    Abstract/FREE Full Text
52. 52.↵
    1. Shields CL,
    2. Meadows AT,
    3. Shields JA, et al

    . Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 2001;119:1269–72 doi:10.1001/archopht.119.9.1269 pmid:11545631

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Turaka K,
    2. Shields CL,
    3. Meadows AT, et al

    . Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer 2012;59:121–25 doi:10.1002/pbc.23278 pmid:21826785

    CrossRefPubMed
54. 54.↵
    1. Luna-Fineman S,
    2. Chantada G,
    3. Alejos A, et al

    . Delayed enucleation with neoadjuvant chemotherapy in advanced intraocular unilateral retinoblastoma: AHOPCA II, a prospective, multi-institutional protocol in Central America. J Clin Oncol 2019;37:2875–82 doi:10.1200/JCO.18.00141 pmid:31536438

    CrossRefPubMed
55. 55.↵
    1. Radhakrishnan V,
    2. Kashyap S,
    3. Pushker N, et al

    . Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology 2012;119:1470–77 doi:10.1016/j.ophtha.2012.01.029 pmid:22463820

    CrossRefPubMed
56. 56.↵
    1. Yamane T,
    2. Kaneko A,
    3. Mohri M

    . The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004;9:69–73 doi:10.1007/s10147-004-0392-6 pmid:15108036

    CrossRefPubMed
57. 57.↵
    1. Abramson DH,
    2. Dunkel IJ,
    3. Brodie SE, et al

    . A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115:1398–404, 404.e1 doi:10.1016/j.ophtha.2007.12.014 pmid:18342944

    CrossRefPubMedWeb of Science
58. 58.↵
    1. Gobin YP,
    2. Dunkel IJ,
    3. Marr BP, et al

    . Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 2011;129:732–37 doi:10.1001/archophthalmol.2011.5 pmid:21320950

    CrossRefPubMedWeb of Science
59. 59.↵
    1. Shields CL,
    2. Bianciotto CG,
    3. Jabbour P, et al

    . Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 2011;129:1399–406 doi:10.1001/archophthalmol.2011.150 pmid:21670328

    CrossRefPubMedWeb of Science
60. 60.↵
    1. Shields CL,
    2. Manjandavida FP,
    3. Lally SE, et al

    . Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the International Classification of Retinoblastoma. Ophthalmology 2014;121:1453–60 doi:10.1016/j.ophtha.2014.01.026 pmid:24656794

    CrossRefPubMed
61. 61.↵
    1. Jabbour P,
    2. Chalouhi N,
    3. Tjoumakaris S, et al

    . Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma. J Neurosurg Pediatr 2012;10:175–81 doi:10.3171/2012.5.PEDS1277 pmid:22793160

    CrossRefPubMed
62. 62.↵
    1. Bonasia S,
    2. Bojanowski M,
    3. Robert T

    . Embryology and anatomical variations of the ophthalmic artery. Neuroradiology 2020;62:139–52 doi:10.1007/s00234-019-02336-4 pmid:31863143

    CrossRefPubMed
63. 63.↵
    1. Shields CL,
    2. Bianciotto CG,
    3. Jabbour P, et al

    . Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol 2011;129:1407–15 doi:10.1001/archophthalmol.2011.151 pmid:21670326

    CrossRefPubMed
64. 64.↵
    1. Marr B,
    2. Gobin PY,
    3. Dunkel IJ, et al

    . Spontaneously resolving periocular erythema and ciliary madarosis following intra-arterial chemotherapy for retinoblastoma. Middle East Afr J Ophthalmol 2010;17:207–09 doi:10.4103/0974-9233.65492 pmid:20844675

    CrossRefPubMed
65. 65.↵
    1. Vajzovic LM,
    2. Murray TG,
    3. Aziz-Sultan MA, et al

    . Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma. Clin Ophthalmol 2011;5:171–76 doi:10.2147/OPTH.S12665 pmid:21383945

    CrossRefPubMed
66. 66.↵
    1. Zanaty M,
    2. Barros G,
    3. Chalouhi N, et al

    . Update on intra-arterial chemotherapy for retinoblastoma. ScientificWorldJournal 2014;2014:869604 doi:10.1155/2014/869604 pmid:25405236

    CrossRefPubMed
67. 67.↵
    1. Monroy JE,
    2. Orbach DB,
    3. VanderVeen D

    . Complications of intra-arterial chemotherapy for retinoblastoma. Semin Ophthalmol 2014;29:429–33 doi:10.3109/08820538.2014.959188 pmid:25325870

    CrossRefPubMed
68. 68.↵
    1. Dalvin LA,
    2. Ancona-Lezama D,
    3. Lucio-Alvarez JA, et al

    . Ophthalmic vascular events after primary unilateral intra-arterial chemotherapy for retinoblastoma in early and recent eras. Ophthalmology 2018;125:1803–11 doi:10.1016/j.ophtha.2018.05.013 pmid:29921454

    CrossRefPubMed
69. 69.↵
    1. Ancona-Lezama D,
    2. Dalvin LA,
    3. Lucio-Alvarez JA, et al

    . Ophthalmic vascular events following intra-arterial chemotherapy for retinoblastoma. Real-world comparison between primary and secondary treatments. Retina 2019;39:2264–72 doi:10.1097/IAE.0000000000002315 pmid:30204728

    CrossRefPubMed
70. 70.↵
    1. Shields CL,
    2. Alset AE,
    3. Say EA, et al

    . Retinoblastoma control with primary intra-arterial chemotherapy: outcomes before and during the intravitreal chemotherapy era. J Pediatr Ophthalmol Strabismus 2016;53:275–84 doi:10.3928/01913913-20160719-04 pmid:27486728

    CrossRefPubMed
71. 71.↵
    1. Dalvin LA,
    2. Kumari M,
    3. Essuman VA, et al

    . Primary intra-arterial chemotherapy for retinoblastoma in the intravitreal chemotherapy era: five years of experience. Ocul Oncol Pathol 2019;5:139–46 doi:10.1159/000491580 pmid:30976594

    CrossRefPubMed
72. 72.↵
    1. Munier FL,
    2. Gaillard MC,
    3. Decembrini S, et al

    . Intracameral chemotherapy (melphalan) for aqueous seeding in retinoblastoma: bicameral injection technique and related toxicity in a pilot case study. Ocul Oncol Pathol 2017;3:149–55 doi:10.1159/000453617 pmid:28868287

    CrossRefPubMed
73. 73.↵
    1. Ramasubramanian A,
    2. Shields CL

    1. Lumbroso-Le Rouic L,
    2. Levy-Gabriel C,
    3. Desjardins L

    . Local adjuvant therapy. In: Ramasubramanian A, Shields CL, eds. Retinoblastoma. New Delhi: Jaypee Brothers Medical Publishers Ltd; 2012
74. 74.↵
    1. Abramson DH,
    2. Frank CM

    . Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 1998;105:573–79; discussion 57 9–80 doi:10.1016/S0161-6420(98)94006-4 pmid:9544627

    CrossRefPubMedWeb of Science
75. 75.↵
    1. Kleinerman RA,
    2. Tucker MA,
    3. Tarone RE, et al

    . Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005;23:2272–79 doi:10.1200/JCO.2005.05.054 pmid:15800318

    Abstract/FREE Full Text
76. 76.↵
    1. Kim JY,
    2. Park Y

    . Treatment of retinoblastoma: the role of external beam radiotherapy. Yonsei Med J 2015;56:1478–91 doi:10.3349/ymj.2015.56.6.1478 pmid:26446627

    CrossRefPubMed
77. 77.↵
    1. Shields CL,
    2. Mashayekhi A,
    3. Sun H, et al

    . Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Ophthalmology 2006;113:2087–92 doi:10.1016/j.ophtha.2006.04.032 pmid:16949158

    CrossRefPubMedWeb of Science
78. 78.↵
    1. Shields CL,
    2. Shields JA,
    3. Minelli S, et al

    . Regression of retinoblastoma after plaque radiotherapy. Am J Ophthalmol 1993;115:181–87 doi:10.1016/s0002-9394(14)73922-4 pmid:8430727

    CrossRefPubMedWeb of Science
79. 79.↵
    1. Ramasubramanian A,
    2. Shields CL

    1. Paramo DM,
    2. Firestone B,
    3. Mahajan A, et al

    . External beam radiation therapy. In: Ramasubramanian A, Shields CL, eds. Retinoblastoma. New Delhi: Jaypee Brothers Medical Publishers Ltd; 2012
80. 80.↵
    1. Ramasubramanian A,
    2. Shields CL

    1. Tsimpida M,
    2. Reddy MA.
    3. Sagoo M

    . Enucleation. In: Ramasubramanian A, Shields CL, eds. Retinoblastoma. New Delhi: Jaypee Brothers Medical Publishers Ltd; 2012
81. 81.↵
    1. de Potter P

    . Current treatment of retinoblastoma. Curr Opin Ophthalmol 2002;13:331–36 doi:10.1097/00055735-200210000-00007 pmid:12218465

    CrossRefPubMed
82. 82.↵
    1. Shields JA,
    2. Shields CL,
    3. Sivalingam V

    . Decreasing frequency of enucleation in patients with retinoblastoma. Am J Ophthalmol 1989;108:185–88 doi:10.1016/0002-9394(89)90015-9 pmid:2757099

    CrossRefPubMedWeb of Science
83. 83.↵
    1. Shields CL,
    2. Uysal Y,
    3. Marr BP, et al

    . Experience with the polymer-coated hydroxyapatite implant after enucleation in 126 patients. Ophthalmology 2007;114:367–73 doi:10.1016/j.ophtha.2006.08.030 pmid:17270685

    CrossRefPubMed
84. 84.↵
    1. Kaliki S,
    2. Shields CL,
    3. Shah SU, et al

    . Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol 2011;129:1422–27 doi:10.1001/archophthalmol.2011.289 pmid:22084213

    CrossRefPubMed
85. 85.↵
    1. Li MH,
    2. Bouffet E,
    3. Hawkins CE, et al

    . Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma. Neurosurg Focus 2005;19:E3 doi:10.3171/foc.2005.19.5.4 pmid:16398467

    CrossRefPubMed
86. 86.↵
    1. de Jong MC,
    2. Kors WA,
    3. Moll AC, et al

    . Screening for pineal trilateral retinoblastoma revisited: a meta-analysis. Ophthalmology 2020;127:601–07 doi:10.1016/j.ophtha.2019.10.040 pmid:32061409

    CrossRefPubMed
87. 87.↵
    1. Rodjan F,
    2. de Graaf P,
    3. Brisse HJ, et al

    . Trilateral retinoblastoma: neuroimaging characteristics and value of routine brain screening on admission. J Neurooncol 2012;109:535–44 doi:10.1007/s11060-012-0922-4 pmid:22802019

    CrossRefPubMed
88. 88.↵
    1. de Jong MC,
    2. Kors WA,
    3. de Graaf P, et al

    . The incidence of trilateral retinoblastoma: a systematic review and meta-analysis. Am J Ophthalmol 2015;160:1116–26.e5 doi:10.1016/j.ajo.2015.09.009 pmid:26374932

    CrossRefPubMed
89. 89.↵
    1. Sirin S,
    2. de Jong MC,
    3. Galluzzi P, et al

    . MRI-based assessment of the pineal gland in a large population of children aged 0-5 years and comparison with pineoblastoma: part II, the cystic gland. Neuroradiology 2016;58:713–21 doi:10.1007/s00234-016-1683-0 pmid:27130617

    CrossRefPubMed
90. 90.↵
    1. Ramasubramanian A,
    2. Kytasty C,
    3. Meadows AT, et al

    . Incidence of pineal gland cyst and pineoblastoma in children with retinoblastoma during the chemoreduction era. Am J Ophthalmol 2013;156:825–29 doi:10.1016/j.ajo.2013.05.023 pmid:23876864

    CrossRefPubMed
91. 91.↵
    1. Gaillard F,
    2. Jones J

    . Masses of the pineal region: clinical presentation and radiographic features. Postgrad Med J 2010;86:597–607 doi:10.1136/pgmj.2009.087460 pmid:20971711

    Abstract/FREE Full Text
92. 92.↵
    1. Imhof SM,
    2. Mourits MP,
    3. Hofman P, et al

    . Quantification of orbital and mid-facial growth retardation after megavoltage external beam irradiation in children with retinoblastoma. Ophthalmology 1996;103:263–68 doi:10.1016/S0161-6420(96)30706-9 pmid:8594512

    CrossRefPubMedWeb of Science
93. 93.↵
    1. Tawansy KA,
    2. Samuel MA,
    3. Shammas M, et al

    . Vitreoretinal complications of retinoblastoma treatment. Retina 2006;26:S47–52 doi:10.1097/01.iae.0000225350.83931.f6 pmid:16946679

    CrossRefPubMed
94. 94.↵
    1. Abramson DH,
    2. Beaverson KL,
    3. Chang ST, et al

    . Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol 2004;122:1316–23 doi:10.1001/archopht.122.9.1316 pmid:15364710

    CrossRefPubMedWeb of Science